Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FP187 versus Fumaderm and placebo in moderate to severe plaque psoriasis
2012-005685-35Phase 3Terminated
- Sponsor
- Forward Pharma
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of FP187-V2B in plaque psoriasis, sponsored by Forward Pharma. Started Jul 2013; status: terminated.
02
Drugs
FP187-V2B
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2012-005685-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005685-35.